In the lab of Dr. Bryan Roth, experiments are underway to remove the powerful hallucinogenic effects from psychedelic drugs.
“There’s one receptor in the brain that psychedelics bind to,” he said, referring to the serotonin 5-HT-2A receptor. “What we’re trying to find is drugs that bind to that receptor (and) activate it, but don’t cause a psychedelic experience and are anti-depressant.”
Read more
The interest in psychedelics and in their usefulness as a tool to help treat a variety of psychiatric conditions is still rapidly growing.
Read more
A new report published in the journal Drug Science, Policy and Law has found that some people who used psychedelics recreationally were able to see and discern colors they hadn’t been able to before. Even more surprising, some said they experienced these vision improvements long after taking psychedelics.
Read more
Psychedelic biotech company PharmaTher Holdings has received FDA approval to study the psychedelic substance ketamine as a treatment for a common drug-induced side effect of Parkinson’s disease treatment.
Read more
First study of its kind shows potential of taking psychedelics in a group setting.
Read more
From the NYTimes: The psychedelic revolution Is coming, and psychiatry may never be the same.
Psilocybin and MDMA are poised to be the hottest new therapeutics since Prozac. Universities want in, and so does Wall Street. Some worry a push to loosen access could bring unintended consequences.
Read more
Great news! The first Phase 3 trial of MDMA-assisted therapy for posttraumatic stress disorder (PTSD) replicated and expanded on Phase 2 results indicating MDMA-assisted therapy may be an effective and cost-saving treatment for PTSD resulting from any cause.
Read more